首页> 美国卫生研究院文献>Endocrinology Diabetes Metabolism Case Reports >Think twice: a rare calcium sensing receptor mutation and a new diagnosis of familial hypocalciuric hypercalcaemia
【2h】

Think twice: a rare calcium sensing receptor mutation and a new diagnosis of familial hypocalciuric hypercalcaemia

机译:三思而三次:稀有钙感应受体突变和家族性低钙血性高钙血症的新诊断

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Distinguishing primary hyperparathyroidism (PHPT) from familial hypocalciuric hypercalcaemia (FHH) can be challenging. Currently, 24-h urinary calcium is used to differentiate between the two conditions in vitamin D replete patients, with urinary calcium creatinine clearance ratio (UCCR) <0.01 suggestive of FHH and >0.02 supportive of PHPT. A 26-year-old Caucasian gentleman presented with recurrent mild hypercalcaemia and inappropriately normal parathyroid hormone (PTH) following previous parathyroidectomy 3 years prior. He had symptoms of fatigue and light-headedness. He did not have any other symptoms of hypercalcaemia. His previous evaluation appeared to be consistent with PHPT as evidenced by hypercalcaemia with inappropriately normal PTH and UCCR of 0.0118 (borderline low using guidelines of >0.01 consistent with PHPT). He underwent parathyroidectomy and three parathyroid glands were removed. His calcium briefly normalised after surgery, but rose again to pre-surgery levels within 3 months. Subsequently, he presented to our centre and repeated investigations showed 24-h urinary calcium of 4.6 mmol/day and UCCR of 0.0081 which prompted assessment for FHH. His calcium-sensing receptor (CASR) gene was sequenced and a rare inactivating variant was detected. This variant was described once previously in the literature. His mother was also confirmed to have mild hypercalcaemia with hypocalciuria and, on further enquiry, had the same CASR variant. The CASR variant was classified as likely pathogenic and is consistent with the diagnosis of FHH. This case highlights the challenges in differentiating FHH from PHPT. Accurate diagnosis is vital to prevent unnecessary surgical intervention in the FHH population and is not always straightforward.
机译:区分初级甲状旁腺功能亢进(PHPT)来自家族性低经性高钙血症(FHH)可能是挑战性的。目前,24小时尿钙用于区分维生素D患者的两个条件,尿钙肌酐清除率(UCCR)<0.01的FHH和> 0.02的PHPT的施用。一位26岁的白种人绅士呈现出反复性轻微高钙血症和在之前的甲状旁腺切除术3年之前的甲状旁腺切除术后不恰当的正常甲状旁腺激素(PTH)。他有疲劳和光明的症状。他没有任何其他高钙血症的症状。他以前的评估似乎与phpt一致,如Higalcalcaemia,与0.0118的不恰当正常的pth和Uccr(使用指南的边界低)与pHPT一致)。他接受了甲状旁腺切除术和三个甲状旁腺。他的钙在手术后短暂标准化,但在3个月内再次升至手术前水平。随后,他介绍了我们的中心,重复的调查显示,24小时尿钙为4.6mmol /天,UCCR为0.0081,促使对FHH的评估。测序他的钙感应受体(CASR)基因,并检测稀有的灭活变体。在文献中以前描述了该变型。他的母亲也被证实有轻微的高血钙血病,并且在进一步调查时,具有相同的Casr变体。 Casr变体分类为致病性,并且与FHH的诊断一致。这种情况突出了区分FHH的挑战。准确的诊断对于防止FHH人口中不必要的手术干预是至关重要的,并且并不总是直截了当。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号